Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Unicycive Therapeutics, Inc. (UNCY) had Return on Tangible Equity of -48.57% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-7.88M |
|
-- |
|
-- |
|
$7.22M |
|
$-7.22M |
|
$-7.44M |
|
$-14.67M |
|
$-14.67M |
|
$-14.67M |
|
$-14.67M |
|
$-14.67M |
|
$-14.67M |
|
$-7.22M |
|
$-7.07M |
|
15.89M |
|
15.89M |
|
$-0.82 |
|
$-0.32 |
|
| Balance Sheet Financials | |
$48.96M |
|
$0.07M |
|
$0.17M |
|
$49.13M |
|
$18.94M |
|
-- |
|
-- |
|
$18.94M |
|
$30.20M |
|
$30.20M |
|
$30.20M |
|
22.11M |
|
| Cash Flow Statement Financials | |
$-31.32M |
|
$-12.10M |
|
$46.47M |
|
$26.14M |
|
$29.20M |
|
$3.06M |
|
$2.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.59 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-31.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-48.57% |
|
|
Return on Tangible Equity |
-48.57% |
-29.85% |
|
-48.57% |
|
$1.37 |
|
$-1.97 |
|
$-1.97 |
|